VDX-111 targets proliferative pathways in canine cancer cell lines
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0303470 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Kristen B Farrell und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, United States of America. Hauptthemen laut MEDLINE: Cell Proliferation, Signal Transduction, Antineoplastic Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
VDX-111 (also identified as AMPI-109) is a vitamin D derivative which has shown anticancer activity. To further assess the function of this compound against multiple cancer types, we examined the efficacy of VDX-111 against a panel of 30 well characterized canine cancer cell lines. Across a variety of cancer types, VDX-111 induced widely variable growth inhibition, cell death, and migration inhibition, at concentrations ranging from 10 nM to 1 μM. Growth inhibition sensitivity did not correlate strongly with tumor cell histotype; however, it was significantly correlated with the expression of genes in multiple cell signaling pathways, including the MAPK and PI3K-AKT pathways. We confirmed inhibition of these signaling pathways as likely participants in the effects of VDX-111. These results suggest that a subset of canine tumors may be sensitive to treatment with VDX-111, and suggests possible predictive markers of drug sensitivity and pharmacodynamic biomarkers of drug exposure that could be employed in future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, United States of America.
- Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
ORCID-Profile: Kristen B Farrell
Förderung
- NHLBI NIH HHS
Zitieren
APA
Farrell, K. B., Das, S., Nordeen, S. K., Lambert, J. R., & Thamm, D. H. (2024). VDX-111 targets proliferative pathways in canine cancer cell lines. PLOS ONE. https://doi.org/10.1371/journal.pone.0303470
Vancouver
Farrell KB, Das S, Nordeen SK, Lambert JR, Thamm DH. VDX-111 targets proliferative pathways in canine cancer cell lines. PLOS ONE. 2024. doi:10.1371/journal.pone.0303470
BibTeX
@article{Farrell2024,
author = {Farrell, Kristen B and Das, Sunetra and Nordeen, Steven K and Lambert, James R and Thamm, Douglas H},
title = {VDX-111 targets proliferative pathways in canine cancer cell lines},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0303470}
}
EUVIMED